Showing results (1451-1460 of 2,739) with videos related to

Sort By:
Pageof 274
Pharmacogenomics|August 2, 2019
GWAS contribution to atrial fibrillation and atrial fibrillation-related stroke: pathophysiological implicationsDiana Cruz, Ricardo Pinto, Margarida Freitas-Silva, et al.
Pharmacogenomics|March 19, 2019
GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patientsMingjun Yu, Kaiyu Wang, Haiming Liu, et al.
Pharmacogenomics|March 19, 2019
Contemporary pharmacogenetic assays in view of the PharmGKB databaseLaurentijn Tilleman, Jana Weymaere, Björn Heindryckx, et al.
Pharmacogenomics|February 20, 2019
Evaluation of the predictive performance of Bayesian dosing for warfarin in Chinese patientsJing Dong, Guo-Hua Shi, Man Lu, et al.
Pharmacogenomics|November 17, 2018
Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviorsLi-Shiun Chen, Sarah M Hartz, Timothy B Baker, et al.
Pharmacogenomics|February 19, 2021
Sociodemographic factors and beliefs about medicines in the uptake of pharmacogenomic testing in older adultsAlexandra Chapdelaine, Catherine Lamoureux-Lamarche, Thomas G Poder, et al.
Pharmacogenomics|March 1, 2017
Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy settingSusanne B Haga, Jivan Moaddeb, Rachel Mills, et al.
Pharmacogenomics|March 1, 2017
No impact of eight NTRK2 genetic polymorphisms on 6-month antidepressant efficacy in depressed patientsEric Deflesselle, Céline Verstuyft, Anne-Cécile Petit, et al.
Pharmacogenomics|March 1, 2017
NFATC1 genotypes affect acute rejection and long-term graft function in cyclosporine-treated renal transplant recipientsQinxia Xu, Xiaoyan Qiu, Zheng Jiao, et al.
Pharmacogenomics|October 8, 2019
CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinomaVolker M Lauschke, Åsa Nordling, Yitian Zhou, et al.
Pageof 274